Overview

Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

Status:
Terminated
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 2a study is to assess changes in tear volume by the non-invasive techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 Ophthalmic Solution or Placebo in subjects with tear deficient dry eye disease.
Phase:
Phase 2
Details
Lead Sponsor:
Parion Sciences
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions